Pokorska-Śpiewak Maria, Śpiewak Mateusz
Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw 01201, Poland.
National Institute of Cardiology, Warsaw 04628, Poland.
World J Hepatol. 2020 Aug 27;12(8):485-492. doi: 10.4254/wjh.v12.i8.485.
In recent years, significant progress in the antiviral treatment of chronic hepatitis C (CHC) has been made due to the development of interferon-free therapies. Three different highly effective, oral direct-acting antiviral (DAA) regimens have been approved for use in adolescents with CHC between the ages of 12-years-old and 17-years-old in Europe. According to the current recommendations, all treatment-naïve and treatment-experienced children with CHC virus infection should be considered for DAA therapy to prevent the possible progression of hepatitis C virus-related liver disease and its complications. However, the novel coronavirus disease 2019 outbreak, which was classified as a pandemic in March 2020, is currently spreading throughout the world, resulting in a disruption of the healthcare system. This disruption is having a negative impact on the care of patients with chronic diseases, including children with CHC. Thus, several efforts have to be made by pediatric hepatologists to prioritize patient care in children with CHC. These efforts include promoting telemedicine in the outpatient setting, using local laboratory testing for follow-up visits, and engaging in the home delivery of DAAs for patients under antiviral therapy whenever possible.
近年来，由于无干扰素疗法的发展，慢性丙型肝炎（CHC）的抗病毒治疗取得了重大进展。在欧洲，三种不同的高效口服直接抗病毒（DAA）方案已被批准用于12至17岁的CHC青少年患者。根据目前的建议，所有未接受过治疗和接受过治疗的CHC病毒感染儿童都应考虑接受DAA治疗，以预防丙型肝炎病毒相关肝病及其并发症的可能进展。然而，2019年新型冠状病毒病疫情于2020年3月被列为大流行病，目前正在全球蔓延，导致医疗系统中断。这种中断正在对慢性病患者的护理产生负面影响，包括CHC儿童患者。因此，儿科肝病学家必须做出多项努力，优先为CHC儿童患者提供护理。这些努力包括在门诊环境中推广远程医疗，在随访时使用当地实验室检测，并尽可能为接受抗病毒治疗的患者提供DAA药物的上门配送服务。
